Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
Adjuvant docetaxel improves survival in women with node-positive disease
July 14th, 2005
Overall survival is improved among women with node-positive breast cancer who receive adjuvant docetaxel compared with those receiving fluorouracil, study results indicate. "We compared docetaxel plus doxorubicin and cyclophosphamide (TAC) with fluorouracil plus doxorubicin and cyclophosphamide (FAC) as adjuvant chemotherapy for operable node-positive breast cancer. We randomly assigned 1,491 women with axillary node-positive breast cancer to 6 cycles of treatment with either TAC or FAC as adjuvant chemotherapy after surgery. The primary end point was disease-free survival," wrote M. Martin and colleagues, Hospital University of San Carlos, Madrid. ...
Source: Women's Health Weekly (2005-07-14)
|
